GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Outperform
ALKS
up 79.75 %

Alkermes, Inc. (ALKS) rated Outperform by Leerink Swann

Posted on: Wednesday,  May 29, 2013  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Alkermes, Inc. (NASDAQ: ALKS) on 05/29/2013, when the stock price was $34.03. Since
then, Alkermes, Inc. has gained 79.75% as of 01/21/2016's recent price of $61.17.
If you would have followed this Leerink Swann 's recommendation on ALKS, you would have gained 79.75% of your investment in 967 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/29/2013 8:25 AM Buy
None
34.03
as of 12/13/2013
1 Week down  -0.87 %
1 Month up  5.19 %
3 Months up  15.22 %
1 YTD up  113.28 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/17/2009 8:25 AM Buy
None
8.58
4/7/2009 9:25 AM Hold
None
8.52
3/3/2009 8:25 AM Buy
None
9.38 13.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy